NovaCardia
Value-based cardiovascular care platform improving patient outcomes
About NovaCardia
Novocardia is the value-based care division of Cardiovascular Associates of America (CVAUSA), focused on transforming cardiovascular care delivery in the United States. Founded in 2020 by Dr. Dan Blumenthal and Dr. Julius Torelli, the company develops, tests, and scales clinical and contracting models designed to enhance the quality, cost, and experience of care for both patients and physicians. In 2023, Novocardia merged with CVAUSA, combining its expertise in value-based care with CVAUSA's extensive clinical footprint to create a large and influential cardiovascular care network in the U.S. Following the merger, Dr. Dan Blumenthal became the president of the Novocardia division within CVAUSA.
The company's business model is centered on partnering with cardiology practices, primary care groups, payers, and risk-bearing entities to facilitate the transition to value-based and risk-based reimbursement models. By providing expertise in clinical service lines, contracting, advanced analytics, and business operations, Novocardia helps its physician partners succeed in these new payment structures. A key partnership includes a multi-state value-based care agreement with Humana to improve care for its Medicare Advantage members.
Novocardia's platform utilizes proprietary technology and analytics to improve patient outcomes and manage costs. Key programs include a Longitudinal Heart Failure Program, which offers comprehensive support and remote monitoring to manage the disease and reduce hospital visits. Other services focus on Site-of-Service Management to deliver care in lower-cost settings, Care Transitions Intervention to streamline the patient journey between different healthcare settings, and ensuring same-day or extended-hours access to specialists. The company leverages risk-stratification modeling and purpose-built actuarial models to track outcomes and understand cost dynamics, ultimately aiming to reduce avoidable hospitalizations and emergency room visits.
Source: Dealroom company dataNews
Open roles
NovaCardia in the San Diego ecosystem
The NovaCardia office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- MPMontreux Equity Partners
InterWest Partners
Skyline Ventures
Series B and later3 investors entered at this stage
Versant Ventures
Domain Associates- FVForward Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about NovaCardia on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NovaCardia on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.